BKC thanks for the perspective. I will actually have to listen to the presentation and get an impression from it other than what I have read.

On your second point (re deal) my problem at this stage (apologies to readers for being a broken record) is that I don't believe Don anymore because of the renege on the Zenith IPO in terms of missing Q4 2015 as promised, backing away from NASDAQ and concocting a story about a reverse take over for a TSX and possibly NASDAQ listings. To me for him to even say that suggests he feels we are complete fools and he has absolutely no respect for the retail side. At this stage I am speculating that KD has Don right where he wants him. As I recall the money flowed into RVX because of the reputation of Dr Norman Wong even though Don may have provided the introduction.

On the development of other molecules this seems to me to be, on one hand, an indication of innovation (afterall what do the scientists do as BoM carries on for 2 years) or it means that rvx-208 is not the answer. We do have the positive results of ASSURE/SUSTAIN re 5 point MACE with 77% RRR in patients with CVD, DM and low HDL. But as fouremm posted Don stated that "we (RVX) have a molecule 13 times more potent than 208". So is rvx-208 inadequate...what is his (Don's) point in stating this? (even though it is good to hear).

I do agree with the points made about inflammatory diseases being a huge issue to which rvx-208 and other BET inhibition compounds seem to be well suited. We have the evidence already for rvx-208 (apabetelone).

So why are there no "bites" from BP. We have an idea that price is an issue but if this stuff really has potential wouldn't AZ be there??? If any BP was in discussions it would be reflrcted in the share price.

One thing I will give Don (and/or Lebioda) credit for is the Hepalink deal. To me this begins to set up the second or third move of the chess game. Obviously Eastern and NGN did not object and must have seen value in it (e.g. funding of ph 3 BoM) and the potential of creating downstream marketing and distribution in 4 countries with over a billion in population and a rapidily growing population with diabetes mellitus and a commitment to health care, and, even when their economy is bad the GDP growth rate is 7%. Chinese capitalists are putting the puzzle together and the support is there in spite of communism.

So one or two more deals like this say in Brazil, Russia, India, South Africa, etc creates an enormous downstream market not just for apabetelone but also all of the follow up compounds at RVX and Zenith as they structure the deals. We must remember that while we all think of the USA as the jewel it only represents 350 million people in a world of 4.5 billion and we know as these other 4 billion people begin to take on lifestyles like the American lifestyles (and eating patterns) that obesity, heart disease, diabetes and cancers will increase rapidly. So the target markets for both the RVX and Zenith product portfolios are growing rapidly and will continue to grow. There is lots of room form competition in these markets.

So I will give Don credit for setting up the early stages of an interesting chess game. BP may not know what will hit them if they get blindsided by epigenetics. I think we all understand that large companies are not innovators and it is quite conceivable that they may wake up to a shock. Don's next move on a new regional deal is key.

I'm not worried about dilution. Why worry about dilution on a factor of 10 on a share worth nothing when the dilution could lead to a share worth $200 (or $20)?

It would be fantastic to see a deal like AZ did with Acerta!!!

Sorry for the rambling. Thanks to all the great posters. I still don't trust Don although he sort of eems shewd!

Cheers

Toinv